Coverage
-
April 23, 2024
The collapse of a massive deal to settle claims Eli Lilly illegally inflated insulin prices may not alter the trajectory of the underlying litigation, as patients are already pressing ahead with a new version of their proposed class action.
2 other articles on this case.
View all »